



Figure S1. Forest plot for 24-week sustained MSFCS composite progression for daclizumab beta versus IM IFN beta-1a by baseline demographics and disease characteristics using alternate definitions for 9HPT.

(A) MSFCS (9HPT using dominant hand only)



(B) MSFCS (9HPT using both dominant and non-dominant hands)



9HPT: 9-Hole Peg Test; CI: confidence interval; EDSS: Expanded Disability Status Scale; Gd+: gadolinium-enhancing; HR: hazard ratio; IFN, interferon; IM: intramuscular; MS: multiple sclerosis; MSFCS: modified Multiple Sclerosis Functional Composite; SC: subcutaneous.